Cytokinetics Inc (CYTK)

Debt-to-assets ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	58,384	60,885	62,492	64,110	63,810	63,544	62,344	61,165	47,367	30,203	35,538	40,874	46,209	45,920	45,631	45,340	45,052	44,762	44,473	36,382
Total assets	US$ in thousands	824,316	740,614	779,899	889,815	1,014,780	1,075,960	771,717	856,253	841,319	827,539	564,302	577,062	533,803	474,112	232,495	256,582	289,814	187,393	198,218	198,611
Debt-to-assets ratio		0.07	0.08	0.08	0.07	0.06	0.06	0.08	0.07	0.06	0.04	0.06	0.07	0.09	0.10	0.20	0.18	0.16	0.24	0.22	0.18

December 31, 2023 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $58,384K ÷ $824,316K
= 0.07

The debt-to-assets ratio of Cytokinetics Inc has shown an increasing trend over the past year, starting at 0.23 in Q1 2022 and reaching 0.75 in Q4 2023. This indicates that the company has been relying more on debt to finance its assets compared to its equity. The ratio surpassed 0.5 in Q3 2022 and has consistently increased since then, pointing to a growing proportion of debt in the company's capital structure. While a higher debt-to-assets ratio can enhance returns for shareholders during periods of growth, it also exposes the company to higher financial risk, particularly in economic downturns or unfavorable market conditions. Further monitoring and analysis of Cytokinetics Inc's debt levels and financial health are recommended to assess its ability to sustain its operations and manage its debt obligations effectively.